# Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer

> **NCT05450029** · PHASE2 · RECRUITING · sponsor: **Yanhong Deng** · enrollment: 51 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT05450029
- **Lead sponsor:** Yanhong Deng
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-01
- **Primary completion:** 2024-01-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2023-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05450029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05450029, "Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05450029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*